5 years 1.17
Extreme 1.17
4.82
10 years 1.17
Extreme 1.17
43.2
Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 56 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.28M
-2.59%-5.70%+40.86%+83.11% 72.13B
+3.23%-13.45%+6.00%+55.77% 49.41B
+1.56%+2.07%+5.03%+33.38% 47.24B
+0.87%-7.83%+296.82%+657.83% 40.32B
+0.39%-0.32%+29.55%+30.83% 42.61B
+1.24%-1.20%+0.96%+103.86% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
+5.32%+0.11%-8.77%-12.81% 23.13B
+3.78%+5.71%+16.43%-1.77% 21.09B
Average +1.17%-3.91%+43.82%+111.17% 40.7B
Weighted average by Cap. +0.78%-4.28%+46.74%+118.77%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14